Tumor Biology

, Volume 37, Issue 3, pp 3115–3121 | Cite as

Synthetic Tet-inducible small hairpin RNAs targeting hTERT or Bcl-2 inhibit malignant phenotypes of bladder cancer T24 and 5637 cells

  • Junhao Lin
  • Yuchen Liu
  • Yonghao Zhan
  • Chengle Zhuang
  • Li Liu
  • Xing Fu
  • Wen Xu
  • Jianfa Li
  • Mingwei Chen
  • Zhiming Cai
  • Weiren Huang
Original Article


Small hairpin RNA (shRNA) can inhibit the malignant phenotypes of tumor cell through ribonucleic acid interference (RNAi). However, it is hardly to be regulated and it may induce few phenotypic changes. Here, we build a type of tetracycline (Tet)-inducible vectors which can achieve regulatable expression of shRNA in a time-dependent manner by using synthetic biology approach. In order to prove the effectiveness of this device, we chose hTERT and Bcl-2 as target genes and test the utility of the device on 5637 and T24 cell lines. The experiments show that the Tet-inducible small hairpin RNA can effectively suppress their target genes and generate anti-cancer effects on both 5637 and T24 cell lines. The device we build not only can inhibit proliferation but also can induce apoptosis and suppress migration of the bladder cancer cell lines 5637 and T24. The Tet-inducible small hairpin RNAs may provide a novel strategy for the treatment of human bladder cancer in the future.


Bladder cancer Tet-inducible shRNA hTERT;Bcl-2 



We are indebted to the donors whose names were included in the author list and the donors who participated in this program. This work was supported by the National Key BasicResearch Program of China (973 Program) (2014CB745201), National Natural Science Foundation of China [81402103], International S&T Cooperation program of China (ISTCP) (2014DFA31050), the Chinese High-Tech (863) Program (2014AA020607), The National Science Foundation Projects of Guangdong Province (2014A030313717), the Shenzhen Municipal Government of China (ZD201111080117A, JCYJ20150330102720130, GJHZ20150316154912494), and Special Support Funds of Shenzhen for Introduced High-Level Medical Team.

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64(1):9–29.CrossRefGoogle Scholar
  2. 2.
    Marta GN, Hanna SA, Gadia R, et al. The role of radiotherapy in urinary bladder cancer: current status. International braz j urol. 2012;38(2):144–56.CrossRefPubMedGoogle Scholar
  3. 3.
    Racioppi M, D’Agostino D, Totaro A, et al. Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. Urologia internationalis. 2011;88(3):249–58.CrossRefGoogle Scholar
  4. 4.
    Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296(5567):550–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proceedings of the National Academy of Sciences. 2002;99(9):6047–52.CrossRefGoogle Scholar
  6. 6.
    Chang HS, Lin CH, Chen YC, et al. Using siRNA technique to generate transgenic animals with spatiotemporal and conditional gene knockdown. The American journal of pathology. 2004;165(5):1535–41.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Seibler J, Kleinridders A, Küter-Luks B, et al. Reversible gene knockdown in mice using a tight, inducible shRNA expression system. Nucleic acids research. 2007;35(7):e54.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kappel S, Matthess Y, Kaufmann M, et al. Silencing of mammalian genes by tetracycline-inducible shRNA expression. Nature protocols. 2007;2(12):3257–69.CrossRefPubMedGoogle Scholar
  9. 9.
    Melissourgos N, Kastrinakis NG, Davilas I, et al. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology. 2003;62(2):362–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Stavropoulos NE, Filiadis I, Ioachim E, et al. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer. Anticancer research. 2001;22(6B):3759–64.Google Scholar
  11. 11.
    Hörner M, Reischmann N, Weber W. Synthetic biology: programming cells for biomedical applications. Perspectives in biology and medicine. 2012;55(4):490–502.CrossRefPubMedGoogle Scholar
  12. 12.
    Betten AW, Roelofsen A, Broerse JEW. Interactive learning and action: realizing the promise of synthetic biology for global health. Systems and synthetic biology. 2013;7(3):127–38.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jain KK. Synthetic biology and personalized medicine. Medical Principles and Practice. 2013;22(3):209–19.CrossRefPubMedGoogle Scholar
  14. 14.
    Ruder WC, Lu T, Collins JJ. Synthetic biology moving into the clinic. Science. 2011;333(6047):1248–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Folcher M, Fussenegger M. Synthetic biology advancing clinical applications. Current opinion in chemical biology. 2012;16(3):345–54.CrossRefPubMedGoogle Scholar
  16. 16.
    Abil Z, Xiong X, Zhao H. Synthetic biology for therapeutic applications. Molecular pharmaceutics. 2014;12(2):322–31.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chappell J, Watters KE, Takahashi MK, et al. A renaissance in RNA synthetic biology: new mechanisms, applications and tools for the future. Current opinion in chemical biology. 2015;28:47–56.CrossRefPubMedGoogle Scholar
  18. 18.
    Fedorenko V, Genilloud O, Horbal L, et al. Antibacterial discovery and development: from gene to product and back. BioMed Research International. 2015;2015:591349.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Liu X, Tang Q, Chen H, et al. Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity. International journal of biological sciences. 2013;9(6):564.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Liu Y, Zeng Y, Liu L, et al. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nature communications. 2014;5:5393.CrossRefPubMedGoogle Scholar
  21. 21.
    Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Research. 1985;45(4):1437–43.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s HospitalThe First Affiliated Hospital of Shenzhen UniversityShenzhenChina
  2. 2.Shantou University Medical CollegeShantouChina
  3. 3.School of Life SciencesSun Yat-Sen UniversityGuangzhouChina

Personalised recommendations